The estrogen-responsive gene Efp promotes the growth of breast cancer cells by stimulating the degradation of a negative cell-cycle regulator, 14-3-3s, and is hence considered a suitable molecular target for breast cancer therapy. The use of small interfering RNA (siRNA) and its derivatives to silence cancer-related genes is being investigated with the aim of identifying clinical applications for these molecules. Recently, it has been shown that DNA-modified siRNA (chimeric siRNA) has good potential in clinical applications, because it induces fewer off-target effects or immune responses in mammalian cells. In the present study, we identified the most specific and effective siRNA (siEfp-1) for silencing Efp expression in MCF-7 breast cancer cells. For this purpose, we used an algorithm that primarily eliminates off-target effects. siEfp-1 considerably suppressed the in vitro proliferation and cell-cycle progression of MCF-7 cells, as well as the in vivo growth of MCF-7 tumors, in athymic mice. DNA-modified siEfp-1 (chimeric siEfp) significantly inhibited the expression of Efp, proliferation of cultured cells and the in vivo growth of MCF-7-derived tumors in athymic mice. In addition, the silencing of Efp expression by siEfp-1 and chimeric siEfp increased the expression of the 14-3-3s protein. These results suggest that siEfp-1 and chimeric siEfp could be useful in breast cancer therapy. Chimeric siEfp, in particular, has a high specificity and induces few side effects and is therefore expected to be used as a novel nucleic acid-based therapeutic agent.
Introduction
Breast cancer is one of the most common types of cancer and is responsible for the second highest number of cancer-related deaths in women. 1 In many cases, primary breast cancer cells express estrogen receptor a (ERa)-a prototypic steroid nuclear receptor that functions as a ligand-dependent transcription factor and induces estrogen-dependent proliferation. 2 We have previously reported that the estrogen-responsive gene (Efp) is a target for estrogen. Efp belongs to the RING finger-B box-coiled coil motif family. 3 The 3 0 -untranslated region of the Efp gene contains an estrogen-responsive element that activates transcription by binding with ERa. 4 In mice, estrogen-induced expression of Efp is observed in tissues such as uterine tissue. 5 Efp-deficient mice exhibit underdeveloped uteri and reduced estrogen responsiveness. 6 In human MCF-7 breast cancer cells, the expression of Efp mRNA is induced in response to estrogen. 4 Clinicopathological studies on breast cancer patients have revealed that Efp immunoreactivity was positively associated with the lymph node status or ERa status and negatively correlated with histological grade. 7 Multivariate analyses of disease-free survival and overall survival of breast cancer patients have revealed that Efp immunoreactivity is correlated with poor prognosis and is an independent marker of breast cancer. 7 Moreover, we showed that Efp promotes the growth of breast tumors by functioning as a ubiquitin E3 ligase that targets the G2/M cell-cycle checkpoint 14-3-3s. 8 Therefore, Efp is considered to be a factor essential in estrogen-dependent cancer proliferation and is a new target of breast cancer therapy.
RNA interference (RNAi) is a novel therapeutic approach for cancer therapy, and involves the specific silencing of therapeutically relevant genes. [9] [10] [11] In particular, chemically synthesized 19 bp long double-stranded small interfering RNA (siRNA) with two-nucleotide 3 0 overhangs is a feasible alternative for cancer treatment that allows the controlled downregulation of cancer-related genes. 12 However, siRNA often induces off-target effects, such as the knockdown of genes other than the target genes, and triggers immune responses, such as the production of inflammatory cytokines and type I interferons. 13, 14 These disadvantages may lead to significant undesirable side effects in mammalian cells. Recently, a new algorithm has been developed to identify highly effective siRNA sequences using novel guidelines that have been established through an extensive study of the relationship between siRNA sequences and RNAi activity. 15, 16 This program also helps to prevent off-target gene silencing by enumerating potential cross-hybridization candidates, which are often overlooked in BLAST searches. Moreover, it has been reported that, in mammalian cells, DNA-modified siRNA (chimeric siRNA)-a derivative of siRNA in which a part of the sequence is substituted with DNA-produces few off-target effects and exhibits low immune response-inducing activity while retaining its substantial gene-silencing activity. 17 These improvements may facilitate the use of siRNA in cancer therapy.
In the present study, we designed an siRNA that specifically and efficiently suppresses Efp expression. We showed that this siRNA significantly inhibited both the in vitro cell-cycle progression and the in vivo tumor growth of MCF-7 breast cancer cells. Chimeric siRNA targeting Efp (chimeric siEfp) inhibited the growth of cultured MCF-7 cells and MCF-7-derived xenografts in athymic mice. We infer that chimeric siEfp will be useful as a novel therapeutic agent for breast cancer treatment.
Materials and methods
Conventional siRNA and chimeric siRNA The siRNA duplexes that target Efp (siEfp-1, 2, 3 and 4) were synthesized using an algorithm that significantly improves the target specificity of siRNA, in particular, by efficiently estimating off-target sequences. 16, 17 A nontargeting control siRNA (siControl) with no homology to the known gene targets in mammalian cells was also synthesized. Chimeric siEfp, in which a part of the siRNA sequence was substituted with DNA, was synthesized on the basis of the siEfp-1 sequence. 15 A chimeric siRNA to be used as the negative control (chimeric siControl) was created by scrambling the sequence of chimeric siEfp. All these siRNAs and chimeric siRNAs were synthesized by RNAi (Tokyo, Japan) ( Table 1) .
Cell culture
Human MCF-7 breast cancer cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin (100 U ml À1 ) and streptomycin (100 mg ml À1 ) at 371C in a humidified atmosphere of 5% CO 2 in air. For experiments conducted in the absence of estrogen, the cells were seeded in an estrogen-deprived culture medium, phenol red-free Dulbecco's modified Eagle's medium, containing 10% dextran-coated charcoal-stripped fetal bovine serum, penicillin and streptomycin for 12 h before siRNA transfection. After the transfection, the media were changed to an estrogen-deprived culture medium containing 100 nM 17b-estradiol (E2) or vehicle (ethanol) and further cultured.
siRNA transfection and western blot analysis MCF-7 cells were plated in six-well plates at a density of 1 Â 10 5 cells per well. The next day, these cells were transfected with either conventional or chimeric siRNA at a final concentration of 150 nM using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). At 36 h after transfection, the cells were lysed in a sample buffer for sodium dodecyl sulfate polyacrylamide gel electrophoresis and heated at 100 1C for 15 min. The cell lysates were resolved by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). The membranes were probed with a rabbit anti-Efp antibody 8 or rabbit anti-14-3-3s antibody (Santa Cruz, Santa Cruz, CA), incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (GE Healthcare, Buckinghamshire, UK) and visualized using enhanced chemiluminescence (GE Healthcare). Membranes were stripped and reprobed with a mouse anti-b-actin antibody (AC-74; SigmaAldrich, St Louis, MO) to verify equal loading of the protein across the lanes.
Quantitative PCR analysis
The MCF-7 cells were transfected with siEfp-1, chimeric siEfp, siControl or chimeric siControl for 36 h. Untransfected cells (À) and cells treated with the transfection reagent alone for 36 h (reagent) were used as controls. Total RNA was extracted from the cells by using Isogen reagent (Nippon Gene, Tokyo, Japan). Real-time quantitative reverse transcriptase-PCR was performed according to a method described in a previous report. 18 Briefly, first-strand cDNA was synthesized from 2 mg of total RNA using SuperScript II reverse transcriptase (Invitrogen) and oligo(dT)20 primer. The mRNA was quantified by real-time PCR using the SYBR Green PCR master mix 
Abbreviation: siRNA, small interfering RNA. 0 . The relative amount of PCR product was calculated by the comparative cycle threshold (Ct) method, using GAPDH as an external control. The experiments were performed in triplicate and the results were represented as mean (s.d.). Student's t-test was used for statistical analysis, and a probability value o0.05 was regarded as statistically significant.
Cell proliferation assay
Cell proliferation was assessed in terms of the cell viability by using a kit containing WST-8 ((2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt; Nacalai Tesque, Kyoto, Japan). MCF-7 cells were seeded on 96-well plates at a density of 4 Â 10 3 cells per well in an estrogen-deprived culture medium and transfected with siEfp-1, chimeric siEfp or negative control siRNA (siControl or chimeric siControl) by using Lipofectamine 2000 (day 0). The final siRNA concentration in the culture medium was 150 nM. At 12 h after transfection, the cells were transferred to an estrogen-deprived culture medium containing 100 nM E2 or vehicle (ethanol). At the indicated time points after transfection, 10 ml of a reagent solution containing WST-8 was added to each well, and the cells were incubated for 4 h at 37 1C. The absorbance of the plates was read on a microplate reader at a wavelength of 450 nm. The results were represented as mean (s.d.; n ¼ 3 in each group). Student's t-test was used for statistical analysis, and a probability value o0.05 was regarded as statistically significant.
Cell-cycle analysis
The MCF-7 cells were plated in an estrogen-deprived culture medium and transfected with siRNA or chimeric siRNA at a final concentration of 150 nM for 12 h. Then, the media were changed to an estrogen-deprived culture medium containing 100 nM E2 or vehicle (ethanol) and cultured for 24 h. The cells were washed once with phosphate-buffered saline and fixed in 70% ethanol. They were then washed twice with phosphate-buffered saline and treated with 16 ml RNase A (10 mg ml À1 ) for 30 min. Finally, they were stained with 10 mg ml À1 propidium iodide (Sigma-Aldrich). The samples were sorted based on DNA content by using fluorescenceactivated cell sorting (FACScalibur; Becton Dickinson, Cockeysville, MD) and CellQuest software (Becton Dickinson) to determine the percentages of cells that were in the G0/G1-, S-and G2/M-phases of the cell cycle.
In vivo antitumor effect of conventional siRNA and chimeric siRNA MCF-7 cells (5 Â 10 5 cells) and Matrigel matrix (Becton Dickinson) were mixed in equal volumes and injected into the flanks of 8-week-old BALB/cAJcl-nu/nu mice (n ¼ 10 and n ¼ 8 in experiments with siEfp-1 and chimeric siEfp, respectively). The tumors were measured in two-dimension using micrometer calipers, and the tumor volume was estimated according to the formula: 0.5 Â ((smallest  diameter) 2 Â (longest diameter)). When the average tumor volume exceeded 150 mm 3 , conventional siRNA or chimeric siRNA duplexes (5 mg) together with 4 ml GeneSilencer reagent (Gene Therapy System, San Diego, CA) dissolved in 50 ml Dulbecco's modified Eagle's medium was directly injected into the tumors twice weekly. The results were represented as mean (s.e.m.). Student's t-test was used for statistical analysis, and a probability value o0.05 was regarded as statistically significant. At the end point of the experiment (6 weeks after siRNA administration), the tumors were dissected from the mice, homogenized in a buffer solution (100 mM Tris-HCl (pH 7.4), 250 mM sucrose and 1 mM phenylmethylsulfonyl fluoride) and subjected to western blot analysis with anti-Efp, anti-14-3-3s and anti-b-actin antibodies.
Results

siEfp and chimeric siEfp inhibit the proliferation of MCF-7 cells
To design the highly effective siRNAs that target human Efp, we used a recently developed algorithm. 16, 17 This program enables the designing of siRNA with maximum target specificity and minimum off-target effects. The induction of off-target effects is one of the most serious problems in the use of RNAi. We designed four Efp siRNAs (siEfp-1-4) ( Table 1 ) and examined their knockdown effects in human MCF-7 breast cancer cells by performing western blot analysis with an anti-Efp antibody (Figure 1a ). Among these siRNAs, siEfp-1 was most effective in suppressing Efp protein expression. In contrast, siEfp-2 and 3 exhibited almost no effect and siEfp-4 exhibited a moderate effect. Control experiments using untransfected cells (À), cells treated with transfection reagent alone (Reagent) or with negative control siRNA (siControl) indicated that siEfp-1 had a high degree of specificity and efficiency in silencing Efp expression (Figure 1b) . Therefore, we used siEfp-1 for further analysis. We next examined the effectiveness of chimeric siEfp. Compared with conventional siRNA, chimeric siRNA is currently considered to be more suitable for in vivo applications, as the latter produces fewer off-target effects, possesses lower immune responseinducing activity and is more stable. 15 We generated chimeric siEfp by substituting several ribonucleotides in the siEfp-1 sequence with DNA (Table 1) . Chimeric siControl was designed by scrambling the sequence of chimeric siEfp-1 and substituting some ribonucleotides with deoxyribonucleotides, as shown in Table 1 . Chimeric siEfp silenced Efp protein expression in MCF-7 cells as efficiently as siEfp-1 did (Figure 1c) . We also showed the silencing effects of siEfp-1 and chimeric siEfp on Efp expression at the RNA level (Figures 1e and f) . Further, as the 14-3-3s protein has been identified as a substrate for Efp ubiquitin ligase, we examined the effects of siEfp-1 and chimeric siEfp on 14-3-3s protein expression. Western blot analysis revealed that transfection with siEfp-1 and chimeric siEfp resulted in an increase in the expression of the 14-3-3s protein in MCF-7 cells (Figure 1d) .
Next, the effect of siEfp-1 and chimeric siEfp on the proliferation of estrogen-dependent MCF-7 cells was investigated using WST-8, which is converted to a water-soluble formazan by metabolically active cells (Figure 2) . The MCF-7 cells grew normally in all the control experiments (with untransfected cells, transfection reagent alone, siControl and chimeric siControl), whereas their proliferation reduced after transfection with siEfp-1 and chimeric siEfp, even in the presence of estrogen.
Chimeric siEfp inhibits cell-cycle progression in MCF-7 cells To determine the effects of siEfp-1 and chimeric siEfp on estrogen-dependent cell-cycle progression, we performed fluorescence-activated cell sorting on MCF-7 cells transfected with siRNA or control siRNA in the presence or absence of estrogen (Figure 3 ). In the estrogen-deprived culture medium, the percentage of cells in the S-phase reduced after transfection with siEfp-1 (20.3%) and chimeric siEfp (21.3%), whereas that of cells in the G0/ G1-phase increased after transfection with siEfp-1 (60.6%) and chimeric siEfp (63.3%), as compared with the results obtained after transfection with siControl (S-phase, 30.9% and G0/G1-phase, 47%) and chimeric siEfp (S-phase, 33.8% and G0/G1-phase, 45.7%) (Figure 3a) . Similarly, in the estrogen-containing medium, the number of cells in the S-phase reduced and that of cells in the G0/G1-phase increased after transfection with the siRNAs (Figure 3b ). These results indicate that chimeric siEfp attenuates the proliferation of cultured MCF-7 cells as effectively as conventional siRNA.
Silencing of Efp by chimeric siRNA suppresses in vivo growth of MCF-7 cells
To assess the effects of siRNA and chimeric siEfp on the in vivo growth of breast cancer cells, we used a xenograft model in which the MCF-7 cells were subcutaneously injected into the flanks of athymic mice. When the average tumor volume exceeded 150 mm siControl (5 mg each) mixed with GeneSilencer transfection reagent was injected into the tumors twice weekly, and the tumor size was measured periodically (Figure 3a) . Under siControl treatment, MCF-7 cells developed into prominent tumors; the average tumor volume at 6 weeks was 457 mm 3 . The administration of siEfp-1 significantly inhibited the growth of MCF-7 tumors. The tumor volume remained almost unchanged throughout the treatment; the average tumor volume at 6 weeks was 189.2 mm 3 (Figures 4a and b) . At 6 weeks after siEfp-1 administration, the tumors were dissected from the mice, and the levels of Efp and 14-3-3s proteins were determined by western blot analysis (Figure 4c ). Cell lysates obtained from tumors in siEfp-1-treated mice contained remarkably reduced amounts of Efp protein, but increased amounts of 14-3-3s protein, as compared with the lysates from tumors in siControl-treated mice. We also investigated the effect of chimeric siEfp on tumor formation by MCF-7 cells, using the same in vivo model. After the administration of chimeric siEfp or chimeric siControl for 6 weeks, the average volume of tumors treated with chimeric siEfp was significantly lower than that of tumors treated with chimeric siControl (567.9 vs 311.2 mm 3 ) (Figures 5a and b) . Western blot analysis of cell lysates from the MCF-7 tumors revealed that Efp protein expression was significantly suppressed as compared with its expression in chimeric siControl-treated tumors (Figure 5c ). However, 14-3-3s expression was elevated in chimeric siEfp-treated tumors. Taken together, these results show that siEfp-1 and chimeric siEfp effectively repress MCF-7-derived tumor growth in mice by specifically inhibiting Efp expression in the cells.
Discussion
In the present study, we designed an effective siRNA that specifically targets Efp (siEfp-1) by using a novel algorithm that was recently developed to maximize the specificity and the efficiency of siRNA. siEfp-1 significantly inhibited the growth of cultured MCF-7 cells and MCF-7-derived xenografts in athymic mice. In addition, chimeric siRNA synthesized using the siEfp-1 sequence (chimeric siEfp) silenced Efp expression and significantly inhibited the proliferation of cultured MCF-7 cells. Chimeric siEfp also suppressed the in vivo growth of MCF-7 tumors in athymic mice. These results suggest that chimeric siRNAs are as suitable for breast cancer therapy as conventional siRNAs.
The results of the cell proliferation assay and evaluation of in vivo tumor growth showed that the efficiency of cell-growth inhibition by chimeric siEfp was slightly lower than that by the unmodified cognate siRNA, siEfp-1. It has previously been reported that gene silencing induced by chimeric siRNA is likely to be less effective than that induced by its unmodified counterparts, because chimeric siRNA exhibits weaker activity for formation of a RNAinduced silencing complex. 15 In the present study, we assumed that a relatively high concentration of siRNA was delivered to the MCF-7 cells. However, in the clinical setting, direct treatment of tumors with high concentrations of siRNAs will be possible in only a few cases. It is generally assumed that siRNAs must be administered through the peripheral veins. However, siRNA administered through this route can be easily degraded. 19 In many cases, siRNA induces the silencing of unintended genes (off-target effects) because of sequence similarity between the mRNAs of the target and nontarget genes. 20 Furthermore, siRNA readily induces immune responses in vivo. 21 These disadvantages can be overcome by the use of chimeric siRNAs, as they produce fewer off-target effects and exhibit lower immunoreactivity than unmodified siRNAs. 15 Ribonucleotides have been modified using artificial chemicals in an attempt to prolong the half-life of siRNA.
14 These chemically modified siRNAs, however, may be more toxic to cells than conventional and chimeric siRNAs synthesized from natural compounds. In addition, the amounts of conventional and chimeric siRNAs required to be injected in mice (10 mg per week) are one-tenth of those of the Efp antisense oligo-DNA (100 mg per week)-a molecule that significantly inhibited the growth of MCF-7 tumors in athymic mice (Po0.01) in our previous study. 8 Although some problems exist in the clinical use of siRNA-based therapy, such as the lack of a suitable drug-delivery system, chimeric siRNA can be expected to supersede unmodified siRNA.
We have previously shown that Efp promotes the growth of breast tumors by functioning as a ubiquitin E3 ligase that targets 14-3-3s. 8 In the present study, treatment with siRNAs targeting Efp caused the upregulation of 14-3-3s protein expression in MCF-7 cells in vitro and in tumors generated from MCF-7 cells in athymic mice, suggesting that these siRNAs could affect the cell-cycle progression of breast cancer cells by stimulating the proteolysis of 14-3-3s. Although 14-3-3s appears to function at a G2 checkpoint, 22 siEfp-1 and chimeric siEfp inhibited the cell-cycle progression of Figure 3 Inhibition of cell-cycle progression by siEfp-1 and chimeric siEfp. MCF-7 cells were seeded in an estrogen-deprived culture medium and transfected with 150 nM siEfp-1, chimeric siEfp or control siRNA (siControl or chimeric siControl) for 12 h. After the transfection, cells were further cultured with the same medium containing vehicle (a) or 100 nM 17b-estradiol (b). Cells were washed with phosphate-buffered saline, stained with propidium iodide and subjected to fluorescence-activated cell sorting. The percentages of cells in the S-, G0/G1-and G2/M-phases were calculated using the CellQuest program.
Knockdown of Efp inhibits breast cancer cell proliferation K Ueyama et al MCF-7 cells at the G0/G1-and S-phases rather than specifically at the G2-phase. Efp has been shown to function as a ubiquitin ligase that can target proteins other than 14-3-3s. 23, 24 It has also been reported that 14-3-3s inhibits the activity of Cdk2/cyclinE to cause G1 arrest. 25 These findings imply that Efp affects cell-cycle progression at multiple phases in addition to the G2-phase.
Almost two-thirds of primary human breast cancers express ERa-a critical factor that determines patient prognosis and the feasibility of endocrine therapy. [26] [27] [28] Endocrine therapy using anti-estrogens or aromatase inhibitors is the most common and most effective treatment for ERa-positive breast cancer; however, many tumors tend to acquire resistance to estrogen during the course of this therapy. [29] [30] [31] ERa-negative breast cancers are originally resistant to endocrine therapy. 32 We have also revealed that Efp is expressed in 70% of breast cancer specimens. Further, Efp has been identified as an independent prognostic factor for breast cancer, regardless of ERa status. 7 Therefore, we expect that if Efp is expressed, siEfp-1 and chimeric siEfp will be used as new therapeutic tools for breast cancer treatment regardless of ERa status and can be used to treat patients with endocrine-resistant or relapsed tumors.
In conclusion, conventional and chimeric siRNAs that are specific for Efp are promising agents for breast cancer therapy. In particular, chimeric siEfp is a novel therapeutic tool as it exhibits high specificity and produces few side effects.
